ClinConnect ClinConnect Logo
Search / Trial NCT05416060

Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age

Launched by SCRIPPS WHITTIER DIABETES INSTITUTE · Jun 10, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Diabetes Health Education M Health Technology Group Education Telehealth Text Based

ClinConnect Summary

The "Dulce Digital 2.0" clinical trial is studying new ways to help people with Type 2 diabetes manage their condition using digital tools. This research aims to improve how individuals, especially those from underserved communities, access and understand important health information online. It compares three methods of teaching diabetes self-management: traditional in-person classes, online classes through telehealth, and simple text messages that encourage healthy habits without needing a smartphone or internet. By finding effective ways to provide education and support, the trial hopes to improve health outcomes for people who face challenges in accessing diabetes care.

To participate in this trial, you must be a Hispanic or Latino adult, a patient at Scripps Health, and have a diagnosis of Type 2 diabetes with a recent blood test showing high blood sugar levels (HbA1c of 8% or higher). However, some individuals may not qualify if they have severe health issues, certain medical histories, or if they cannot read or write well enough to participate in the text messaging program. If you join, you can expect to receive education and support tailored to your needs, all while helping improve diabetes care for others in your community.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Hispanic/Latino adults who are registered patients of Scripps Health
  • Diagnosis of Type 2 Diabetes
  • HbA1c greater than or equal to 8% within the last 60 days
  • Exclusion Criteria:
  • Severe illness precluding visits to clinic
  • Liver function tests (ALT and AST) \> 3 times the upper limit of normal
  • Body mass index ≤ 23 kg/cm
  • History of malignancy, except subjects who have been disease-free for \>2 years, or whose only malignancy has been basal or squamous cell skin carcinoma
  • Creatinine \>3.5
  • History of drug or alcohol abuse within 12 months prior to randomization
  • Current enrollee in DSME/S
  • Blood donation of one pint or more within the past 30 days, or plasma donation within 7 days prior to screening
  • Anemia
  • Lack of minimal literacy needed to participate in the text intervention
  • Severe auditory or visual problems
  • Primary language other than Spanish or English
  • Not willing to carry a mobile phone
  • Pregnant
  • Plans to relocate

About Scripps Whittier Diabetes Institute

The Scripps Whittier Diabetes Institute is a leading clinical research organization dedicated to advancing the understanding and treatment of diabetes and related metabolic disorders. As a part of the renowned Scripps Research network, the Institute focuses on innovative research, cutting-edge clinical trials, and the development of effective therapeutic interventions. With a multidisciplinary team of experts in endocrinology, nutrition, and behavioral health, the Scripps Whittier Diabetes Institute is committed to improving patient outcomes through rigorous scientific inquiry and a patient-centered approach to care.

Locations

San Diego, California, United States

Chula Vista, California, United States

Patients applied

0 patients applied

Trial Officials

Athena Philis-Tsimikas, MD

Principal Investigator

Scripps Health

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials